[View original text]

Participated in AI precision medical solution ‘DrAnswer 2.0’ development project

AIDOT will develop thyroid cancer recurrence prediction software with the Medical Artificial Intelligence Team of Chungbuk National University Hospital.

On 10th of May, AIDOT announced that it will participate in the development project of "DrAnswer 2.0," an artificial intelligence (AI) precision medical solution organized by the Ministry of Science and ICT, and develop thyroid cancer recurrence prediction software by 2024.

The second project of DrAnswer called 'DrAnswer 2.0', aims to improve public health and quality of life by developing AI medical software for 12 diseases such as pneumonia and liver disease, improving the quality of medical service and reducing medical expenses.

AIDOT develops software to predict the recurrence of thyroid cancer, one of the 12 diseases selected for DrAnswer 2.0. Accordingly, by 2023, AIDOT will complete the development of a prediction model for thyroid cancer recurrence and software prototypes. It also plans to commercialize it in earnest from 2024 by combining it with the carotid ultrasound artificial 

intelligence screening system, which is undergoing licensing.

Kang-bin Lee, head of the service development team at the AIDOT R&D team said, "Since thyroid cancer is a disease that has a high probability of recurrence and is prone to spread to other areas, truly hope this project will help many patients get out of their worries about recurrence."

Meanwhile, in addition to the thyroid cancer recurrence prediction program, AIDOT is △ Cerviray AI, an artificial intelligence diagnosis system for cervical cancer △ Sonodot AI, a 

preventive carotid artery diagnosis system for stroke △Gigadot AI, a real-time digestive endoscopic examination system, has been developed and is promoting commercialization. In 

addition, it was selected as a demonstration special operator of the Health Insurance Review and Assessment Service and a special regulatory zone in Gangwon-do, respectively, and 

developed a ureter absence artificial intelligence system and an artificial intelligence liver disease pre-diagnosis system.

10th. May. 2022. / Pharm News / Reporter Tae-il Kim